Objective To investigate the clinical distribution and the drug resistance of Acinetobacter baumannii, and to provide guidance for clinical medication. Methods Specimens were collected from clinical patients with infection from January to December in 2012.Strains of Acinetobacter baumannii were isolated and the drug sensitivity was tested retrospectively. Results A total of 309 strains of Acinetobacter baumannii were isolated, sputum was the main specimen from which Acinetobacter baumannii were isolated (88.03%). Acinetobacter baumannii was mainly distributed at ICU (50.16%). These strains were susceptible to colistin and polymyxin, the drug resistance rate of which is lower than 10%. The drug resistance rate to cefoperazone/sulbactam was 17.5%. The drug resistance rate to other 19 antibiotics was higher than 50%. The highest resistance rate was 100%, which was cefoperazone, to norfboxacin and to ofloxacin. Conclusions Acinetobacter baumannii is susceptible to colistin, polymyxin and cefoperazone/sulbactam. In order to provide the basic evidence for selecting the antibiotics reasonably in clinic, we should strengthen monitoring the drug resistance of Acinetobacter baumannii. Meanwhile we should take effective preventive measures to avoid outbreak of Acinetobacter baumannii infection to avoid outbreak. Antimicrobial agents should be used rationally to decrease multi - drug resistance.